Abstract: A defoaming composition is composed of a composition E composed of a hydrogen bond donor polyether modified polysiloxane C and a hydrogen bond acceptor X, and a composition F composed of a hydrogen bond donor fatty alcohol polyether D and a hydrogen bond acceptor Y; and the polyether modified polysiloxane C is composed of a polyorganosiloxane A and an allyl polyether B. The general structural formula of the polyorganosiloxane A is R02HSiO (Me2SiO)aSiHR02, where R0 is C1-12 alkyl, cycloalkyl or aryl, and a=10-100. The general structural formula of the allyl polyether B is CH2?CHCH2(OCH2CH2)b(OCH2CHCH3)cOH, where b=1-10, and c=10-100. The general structural formula of the fatty alcohol polyether D is R1(OCH2CH2)m(OCH2CHCH3)nOH, where R1 is C3-20 linear or branched alkyl, cycloalkyl or aralkyl; m=1-50; and n=10-100. The hydrogen bond acceptors X and Y are menthol, menthene, thymol, terpilenol, carveol or perillyl alcohol.

Abstract: A heating, ventilation, and air conditioning (HVAC) system includes a fan wheel, a motor directly coupled to the fan wheel and configured to drive rotation of the fan wheel, and an enclosure. The enclosure includes a first side panel, a second side panel, and a curved panel extending from the first side panel to the second side panel to define an internal volume of the enclosure. The first side panel includes an air inlet opening formed therein, the second side panel includes a main panel and a cover panel configured to removably couple to the main panel, the main panel includes an opening and a slot formed therein, the motor is configured to be disposed at least partially within the opening and to mount to the second side panel in an assembled configuration of the blower assembly, the cover panel is configured to occlude the slot in the assembled configuration, and the motor and the fan are removable from the enclosure via the slot.

Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.

Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

Abstract: The application provides to methods for treating Hodgkin lymphoma or non Hodgkin lymphoma in a subject comprising—nivolumab, or pembrolizumab, two PD-1-blocking antibodies that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma in combination with—an anti CD30 antibody, such as brentuximab vedotin.